NeoGenomics (NGNM) Inks $1M Licensing Agreement with Health Discovery (HDVY)
NeoGenomics Inc., a leading provider of cancer-focused genetic testing services, today announced that it has licensed the exclusive worldwide rights to use Health Discovery Corp.’s (HDC) intellectual property portfolio to develop laboratory developed tests (LDTs) and other products relating to hematopoietic and solid tumor cancers, excluding retina and breast cancer. "Our agreement with HDC is an important strategic building block for NeoGenomics. We are executing well on the fundamentals of providing high-quality service, and have developed strong market-based partnerships with leading pathologists and clinicians. The ability to develop and successfully market innovative and proprietary genetic and molecular-based tests is an…